Key facts
- Nanopath’s last known valuation is $32.0M (Aug 2022).
- It has raised $16.4M across 2 recorded rounds; the latest was Early Stage VC ($10.0M) in Jun 2022.
- Notable investors include Alumni Ventures, Creative Destruction Lab, US National Science Foundation, Service Provider Capital, National Institutes of Health — 17 tracked in total.
- Nanopath has filed 2 Form Ds with the SEC since 2022, most recently Feb 2025 ($5.3M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Nanopath
Funding rounds
2 roundsAbout Nanopath
Developer of a molecular diagnostic platform designed to enable point-of-care disease diagnosis. The company's technology eliminates the need for nucleic acid amplification and supports multiplexed detection, enabling patients and providers to access actionable diagnostic results within standard office visits for improved healthcare outcomes.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Employees
- 23
- Website
- nanopath.com/
- Ownership
- Privately Held (backing)
Nanopath doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nanopath shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nanopath in its N-PORT filings yet. We sweep new filings monthly.